参考来源: Avacta announces positive new data from the AVA6000 phase 1 trial demonstrating clinically meaningful tumor shrinkage in patients with salivary gland cancers. New Release. Avacta Therapeutics. January 16, 2025. Accessed January 17, 2025. A study evaluating the safety, pharmacokinetics and ...
https://www.targetedonc.com/view/approaching-treatment-for-a-patient-with-nsclc-and-an-egfr-mutation [2]https://avacta.com/avacta-announces-first-patient-dosed-in-ava6000-pro-doxorubicin-phase-1-clinical-trial/ 关于我们: 盛诺一家...
The peptide moiety linker (pre|CISIONTM) prevents cellular entry of doxorubicin unless cleaved by FAP, thus enabling targeted delivery of doxorubicin to tumors.Design: The safety, PK and preliminary efficacy of AVA6000 was studied in a first-in-man, multicenter dose escalation phase I trial. AV...
A minor response (14.6% reduction in SLD at first 8-week scan) in a 65-year-old female patient with SGC who remains on the trial. This patient was dosed in the 250 mg/m2 Q2W cohort of the trial and had progression on a prior line of therapy. This patient continues on study. Simil...
(AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics announces that AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical...
Avacta announces positive new data from the AVA6000 phase 1 trial demonstrating clinically meaningful tumor shrinkage in patients with salivary gland cancers. New Release. Avacta Therapeutics. January 16, 2025. Accessed January 17, 2025. A study evaluating the safety, pharmacokinetics and early effica...
fibroblasts alone. A 15% reduction in parotid and lymph nodal lesions continues at the 12 weeks post scan. This patient began treatment in September 2024 following two prior lines of therapy to which ...
Avacta Group announced that the first patient has been dosed in its phase I multicentre trial evaluating AVA6000, a novel pro-drug of doxorubicin. AVA6000 is Avacta’s first therapeutic based on its proprietary pre|CISION technology. The platform incorporates a substrate that is specifically cleav...
“We look forward to providing additional updates as the dose-escalation phase of the trial progresses.” References AVA6000 receives orphan drug designation from the US Food and Drug Administration. News release. Avacta Group plc. September 5, 2022. Accessed September 7, 2022. https://bit.ly...
the US, which has the potential to meaningfully impact patients with difficult-to-treat tumours. The clearance of the AVA6000 IND by the FDA enables the opening of key US sites to support the ALS-6000-101 clinical trial which is currently recruiting patients across clinical sites in the UK....